Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Joshua Field

Hematology & Oncology Milwaukee, WI Medical Doctor

NPI 1609938067 CMS profile 807577

9200 W Wisconsin Ave, Division Of Neoplastic Diseases, Milwaukee, WI 53226

Open in the dashboard

General payments

$16

1 record reported · program years 2021–2023

Research payments

$15,316

Paid to them · 1 record reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$191,512 paid to institutions, not to them · program years 2019–2024

Through program year 2023, Joshua Field of Milwaukee, WI is reported in the CMS Open Payments database as having received $16 across 1 general payment and $15,316 in research payments paid to them. Separately, studies naming them as principal investigator received $191,512 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $16 1
2021 Research $15,316 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Field
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Joshua Field were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Joshua Field Hematology & Oncology median Middle half National median
2019 $0 $529 $121–$2,516 $163
2020 $0 $339 $82–$2,213 $114
2021 $0 $263 $49–$1,965 $132
2022 $0 $416 $103–$2,395 $149
2023 $16 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Chiesi USA, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Education $16 1 payment
Products named General payments · program years 2021–2023
  1. FERRIPROX $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2023
  1. Rigel Pharmaceuticals, Inc. $15,316 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,528

Median for Hematology-Oncology: 604

Drug cost

$1,211,221

Median for Hematology-Oncology: $1,306,514

Branded share of claims

39.1%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Empaveli Pegcetacoplan Brand 13 $498,012
Jakafi Ruxolitinib Phosphate Brand 22 $374,356
Eliquis Apixaban Brand 186 $154,154
Xarelto Rivaroxaban Brand 76 $71,797
Deferasirox Generic 22 $42,371
Oxycontin Oxycodone Hcl Brand 93 $33,375
Enoxaparin Sodium Generic 43 $14,441
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 146 $7,522
Xtampza Er Oxycodone Myristate Brand 35 $5,305
Oxycodone Hcl Generic 510 $3,764

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$29,750

Medicare's payments for the services billed

Medicare patients

243

Average age 66

Services billed

395

135 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 46%
Chronic kidney disease 39%
Diabetes 34%
Ischemic heart disease 33%
Heart failure 31%
Depression 29%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record